氟达拉滨联合阿仑单抗（FA）一线治疗具有不良生物学特征的年轻慢性淋巴细胞白血病（CLL）患者。
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile.
机构信息
Hematology, Department of Cellular Biotechnologies and Hematology, "Sapienza" University, Rome, Italy.
Oncologia Medica, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy.
出版信息
Leuk Res. 2014 Feb;38(2):198-203. doi: 10.1016/j.leukres.2013.11.009. Epub 2013 Nov 19.
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
在 45 岁至 60 岁患有 CLL 且生物学特征不良的患者中，一线治疗采用氟达拉滨和坎帕斯（阿仑单抗）。总缓解率为 75.5%，完全缓解率（CR）为 24.4%，11q 和 17p 缺失病例的 CR 率最低，分别为 16.7%和 8.3%。3 年无进展生存（PFS）和总生存率分别为 42.5%和 79.9%。PFS 显著受 CLL 持续时间、β2-微球蛋白影响，经缓解后干细胞移植可改善。一线氟达拉滨联合阿仑单抗在具有不良生物学特征的小系列 CLL 患者中表现出可管理的安全性和获益证据。
Zotero 插件